RESEARCH TRIANGLE PARK – Just days after landing a $44 million contract to see if its investigational anti-viral drug, galidesivir, is effective in treating the COVID-19 coronavirus, BioCryst has secured a $7 million order from the federal government for its influenza therapy known as Rapivab.

The contract covers 10,000 doses and is part of a $34.7 million agreement signed in 2018 with the Centers for Disease Control and Prevention.

“There is great concern for the potential impact on the healthcare system in general, and hospitals in particular, of the upcoming influenza season in the midst of the COVID-19 pandemic. RAPIVAB is an important antiviral with proven benefits for influenza patients, and we appreciate the opportunity to deliver more RAPIVAB to the SNS to hold as a supplement for public health authorities and healthcare facilitites that might need it at this critical time,” said Jon Stonehouse, chief executive officer of BioCryst.

The latest order was announced Thursday.

Durham’s BioCryst lands $44M contract to test anti-viral drug against COVID-19 virus